Last reviewed · How we verify
SR Cornea Consultants — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Prednisolone Acetate 1% Oph Susp | Prednisolone Acetate 1% Oph Susp | marketed | Corticosteroid | Glucocorticoid receptor | Ophthalmology | |
| dexamethasone intraocular suspension, 9% | dexamethasone intraocular suspension, 9% | marketed | Corticosteroid | Glucocorticoid receptor | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AIDS Malignancy Consortium · 1 shared drug class
- ANI Pharmaceuticals · 1 shared drug class
- AbbVie · 1 shared drug class
- Acrotech Biopharma Inc. · 1 shared drug class
- Allergan · 1 shared drug class
- Aramis Biosciences, Inc. · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for SR Cornea Consultants:
- SR Cornea Consultants pipeline updates — RSS
- SR Cornea Consultants pipeline updates — Atom
- SR Cornea Consultants pipeline updates — JSON
Cite this brief
Drug Landscape (2026). SR Cornea Consultants — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sr-cornea-consultants. Accessed 2026-05-17.